NOVEMBER 30, 2021. The University of South Florida (USF) patented two new medical treatment technologies today.
The University of South Florida (Tampa, Florida) secured U.S. Patent 11,185,261 for non-invasive blood glucose monitoring. The American Diabetes Association estimates that nearly 10% of the population in the United States has diabetes and that, by 2050, 1 in 3 Americans will have diabetes. Elevated glucose levels in the blood, known as hyperglycemia can cause heart disease, kidney disease, strokes, vision loss, and amputation. Self-monitoring of glucose levels helps treatment decisions in insulin and non-insulin use patients with diabetes.
Continuous glucose monitoring (CGM) devices require a disposable needle-like insertion into the body, which lasts only up to a week. Most non-invasive glucose monitoring systems face the challenge of being susceptible to external interference from other factors such as body temperature, perspiration, skin moisture, changes in skin thickness and body movement.
To solve this, USF researchers invented a patch antenna that measures blood glucose levels based on the measured shift of its resonant frequency. This voltage shift is then fed to a microcontroller to convert the values into real-time glucose concentration.
Steven Saddow was the lead inventor. Joint-inventors included Fabiola Cespedes, Gokhan Mumcu and Christopher Frewin. Molly Sauter prosecuted the patent on behalf of Smith & Hopen.
COPD Treatment and Therapy
USF also secured U.S. Patent 11,185,528 on Nov. 30, 2021, for treating, among other diseases, COPD. Endothelial dysfunction and changes in vascular permeability are key events in many allergic diseases including edema and chronic obstructive pulmonary disease (COPD). USF researchers found that Alda-1 (benzodioxyl dichlororobezamide) decreased oxidative stress and inflammation. This reduced damage to pulmonary cells to help prevent lung injury.
Narasaiah Kolliputi was the lead inventor. Joint-inventors included Richard Lockey and Lakshmi Galam. Attorney Michele Lawson prosecuted the patent on behalf of Smith & Hopen